• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pediatrics

The MORDOR II trial: mass azithromycin distribution decreases childhood mortality in Niger

byDayton McMillan
June 8, 2019
in Pediatrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Mass, twice-yearly administration of azithromycin to children between 1 and 59 months of age in communities in Niger previously not administered azithromycin significantly reduced childhood mortality rates.

2. Communities given azithromycin for a third year, after receiving it the previous 2 years, had no significant change in childhood mortality rates.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: A prior, related tria lMORDOR I showed that twice-yearly azithromycin administration to children in various African countries reduced childhood mortality significantly. There was possibility that if administration were continued, antibiotic resistance could develop and reduce the efficacy of treatment. There was also the potential for increased efficacy through reduction of sensitive bacteria in the community. The MORDOR II (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) trial evaluated childhood mortality in various Niger communities who had and had not received azithromycin the previous 2 years. Childhood mortality rates in communities who had and had not previously received azithromycin were similar. In communities not previously administered azithromycin notable reductions in childhood mortality rates were observed.

This study provides additional follow-up to suggest continual community antibiotic treatment in certain countries may reduce childhood mortality rates. It is limited in scope of study to community level data and by a single country sample as opposed to multiple countries in the previous associated trial. Long term effects will also need to be evaluated prior to considering wider administration schemes.

Click to read the study in NEJM

Relevant Reading: Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study

RELATED REPORTS

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

Addition of azithromycin to standard treatment does not improve survival in childhood diarrhea

Wellness Check: Nutrition

In-Depth [prospective cohort]: This prospective cohort trial was conducted from 2017 to 2018. Communities (n=594) identified in Niger for study inclusion were already identified from the MORDOR I trial. All children age 1 to 59 months and weighing at least 3800g were eligible for treatment with azithromycin. Twice yearly dosing for one year of 20mg of azithromycin per kg of body weight was given. Mortality rates were established via community census data collected during the study. Approximately 92% of the target population in the communities received azithromycin. Mortality rates per 1000 person-years were comparable between communities who had received azithromycin for the first time (24.0, 95% confidence interval [CI], 22.1 to 26.3) and the prior 2 years (23.3 deaths, 95% CI, 21.4 to 25.5). The first year of treatment did not show a greater mortality reduction effect compared to the third year of treatment (P=0.55). In communities not previously receiving azithromycin a significant childhood mortality reduction of 13.3% was observed (95% CI, 5.8 to 20.2; P = 0.007). There was no significant difference in mortality rates between the first two years of treatment and the third year in communities already administered azithromycin (−3.6%; 95% CI, −12.3 to 4.5; P = 0.50). No serious adverse events were determined to be caused by azithromycin.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Africaazithromycinchildhood mortalityNiger
Previous Post

The VADT-F trial: major cardiovascular events or death are not reduced in diabetics with intensive glucose control therapy

Next Post

Quick Take: Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma

RelatedReports

Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

March 16, 2022
Growth Faltering is Associated With Altered Brain Functional Connectivity and Cognitive Outcomes In Urban Bangladeshi Children Exposed to Early Adversity
Pediatrics

Addition of azithromycin to standard treatment does not improve survival in childhood diarrhea

February 18, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

February 17, 2022
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Chronic Disease

Mass administration of three-dose azithromycin reduces community prevalence of yaws

January 17, 2022
Next Post
Modified FOLFIRINOX results in longer disease-free survival in metastatic pancreatic cancer patients compared to gemcitabine

Quick Take: Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma

Quick Take: Effect of Intraoperative High Positive End-Expiratory Pressure (PEEP) With Recruitment Maneuvers vs Low PEEP on Postoperative Pulmonary Complications in Obese Patients

Decline in pediatric herpes zoster associated with varicella vaccine

Decline in pediatric herpes zoster associated with varicella vaccine

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Sleep
  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.